Soluble PD‑L1 reflects cachexia status in patients with gastric cancer and is an independent prognostic marker for relapse‑free survival after radical surgery.

Autor: Matsumoto Y; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Sasaki T; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Kano M; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Shiraishi T; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Suito H; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Murakami K; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Toyozumi T; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Otsuka R; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Kinoshita K; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Iida S; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Morishita H; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Nishioka Y; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Hayano K; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Kurata Y; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Hayashi H; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan., Matsubara H; Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 2608670, Japan.
Jazyk: angličtina
Zdroj: Molecular and clinical oncology [Mol Clin Oncol] 2023 Mar 20; Vol. 18 (5), pp. 39. Date of Electronic Publication: 2023 Mar 20 (Print Publication: 2023).
DOI: 10.3892/mco.2023.2635
Abstrakt: Soluble programmed death-ligand 1 (sPD-L1) levels can be used as a biomarker for gastric cancer (GC). However, comprehensive information regarding the sPD-L1 expression profiles and their association with cachexia in GC is lacking. Therefore, the present study evaluated the association between clinicopathological findings and sPD-L1 levels in patients with GC. Serum samples were collected from patients with GC during their first visit to Department of Esophageal-Gastro-Intestinal Surgery, Chiba University Hospital, Chiba, Japan (January 2012-December 2017; n=173), and sPD-L1 levels were measured using an enzyme-linked immunosorbent assay. Survival rates among 116 patients, excluding cases with preoperative chemotherapy or no radical procedures, were analyzed. sPD-L1 levels were associated with factors such as neutrophil-to-lymphocyte ratio, hemoglobin (Hb) and albumin (Alb) levels, total cholesterol and C-reactive protein (CRP) levels, and related to inflammation and nutrition in patients. Notably, the higher the number of applicable indicators related to cachexia (Hb <12 g/dl, Alb <3.2 g/dl, CRP >0.5 mg/dl and low body mass index) was, the higher the sPD-L1 value was. However, the pathological stage did not significantly differ between the groups. Clinicopathologically, there was no association with tumor depth, lymph node metastasis or vascular invasion; however, patients with the intestinal type had significantly higher sPD-L1 levels than patients with the diffuse type (P=0.032; Wilcoxon test). The overall survival did not significantly differ between the groups with low and high sPD-L1 levels; however, among patients who received radical treatment, the relapse-free survival was significantly worse in the high-sPD-L1-level group than in the low-sPD-L1-level group (P=0.025; log-rank test). Multivariate Cox regression analysis revealed that a high sPD-L1 concentration was a sign of poor prognosis, independent of pathological stage and cancer antigen CA19-9 (P=0.0029). Therefore, the present findings suggest that sPD-L1 can reflect cachexia status in patients with GC and may serve as a prognostic marker for relapse-free survival after radical GC surgery.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © Matsumoto et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje